Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients
Key Highlights
- ➤DurAVR THV one-year outcomes will be presented from 100 severe aortic stenosis patients
- ➤Rishi Puri, MD, PhD, will present the late-breaking data at PCR London Valves
- ➤Presentation covers clinical and hemodynamic outcomes in patients with small aortic annuli
- ➤Anteris’ DurAVR THV is a biomimetic, balloon-expandable transcatheter heart valve
Expert Statements
Rishi Puri, MD, PhD, Cleveland Clinic
“One-Year Clinical and Hemodynamic Outcomes of a Novel Biomimetic Balloon-Expandable THV in Small Aortic Annuli”
MINNEAPOLIS and BRISBANE, Australia, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (Nasdaq: AVR; ASX: AVR) today announced that Rishi Puri, MD, PhD, Cleveland Clinic, will present one-year clinical and hemodynamic outcomes for the DurAVR(®) Transcatheter Heart Valve (THV) in a late-breaking session at PCR London Valves, held November 22–24, 2026, in London, United Kingdom.
The presentation will report one-year clinical and hemodynamic outcomes from a pooled cohort of 100 patients with severe aortic stenosis who received the DurAVR THV. The DurAVR THV is a biomimetic, balloon-expandable valve and a new class of transcatheter aortic valve replacement (TAVR).
Get started
Create a free account to read the full story.
